An industry veteran and former Ace Vision
Group Board of Director, Frank Chen
brings business operations, regulatory strategy and investment
expertise to support the Company's next phase of growth and
innovation.
BOSTON, June 20,
2024 /PRNewswire/ -- Ace Vision Group, Inc., an
emerging medical device company at the forefront of pioneering a
laser microporation therapy for the aging eye, today announced the
appointment of Frank Chen as Chief
Operating Officer (COO). Mr. Chen brings extensive management to
enhance operational efficiencies and drive business growth at Ace
Vision Group (AVG).
With over 20 years of experience in the healthcare industry, Mr.
Chen has held key leadership roles in established companies and
startups, consistently driving growth and operational excellence.
Before being named COO, Mr. Chen was President of Santen Ventures,
Inc., responsible for operations, business development, and
investments in best-in-class biotech startups.
Mr. Chen has invested in a variety of companies and achieved
multiple exits. Having served on the AVG Board of Directors,
he has now returned to help guide AVG as it establishes its
treatment of age-related vision loss.
"We are excited to welcome back a talented, trusted leader who
embodies a combination of strengths that is ideal to move us
forward," said Dr. AnnMarie Hipsley,
CEO of Ace Vision Group. "Frank's strategic vision and operational
expertise will be instrumental in guiding Ace Vision Group through
its next phase of stages of innovation, clinical research and
commercialization."
Mr. Chen began his career in clinical care, where the
transformative impact of new therapies on patient lives inspired a
determination to spend his career supporting innovation. He spent
nearly a decade as a senior scientist in medical device development
at Johnson & Johnson, where he added expertise in leadership by
honing his skills in the Lean Six Sigma management process.
He then transitioned to business consulting, assisting top
pharmaceutical companies with technology transformation, digital
marketing, and commercial readiness. At Ace Vision Group,
he will oversee daily operations, ensuring the Company's
strategic initiatives are effectively implemented across all
departments. He will work closely with the entire executive team as
the Company prepares to bring its novel touchless eye laser therapy
to patients with age-related vision loss.
"As a board member, I saw the life-changing impact of Laser
Scleral Microporation Therapy," said Mr. Chen. "I'm thrilled to
rejoin Ace Vision Group as an officer of the company to help
advance the Company's core technology."
About Ace Vision Group
Ace Vision Group, Inc. (AVG) is a privately held U.S.
ophthalmic medical device company developing Laser Microporation
Therapeutic technologies to address age-related eye dysfunction and
address the eye's natural biomechanical performance. AVG's Laser
Scleral Microporation (LSM) is a therapeutic eye laser treatment
that aims to restore visual function naturally without sacrificing
distance vision. AVG's brand promise is to provide the field of
ophthalmology with innovative devices, Microporation Therapeutic
procedures, and education for the treatment of age-related ocular
dysfunction, disability, and disease. For more information about
Ace Vision Group please visit www.acevisiongroup.com.
Media Contacts
Niko Perrin
nperrin@acevisiongroup.com
Ashley Murphy
Ashley.murphy@precisionaq.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ace-vision-group-strengthens-executive-team-with-addition-of-frank-chen-as-chief-operating-officer-302177193.html
SOURCE Ace Vision